• PDF / 169,984 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 94 Downloads / 159 Views

DOWNLOAD

REPORT

---

1

S

Deep vein thrombosis: case report In a retrospective study of 34 patients received maintenance therapy between March 2009 and December 2018, one patient [age and sex not stated] was described, who developed massive deep vein (DVT) thrombosis during treatment with bortezomib and dexamethasone for newly diagnosed transplant eligible multiple myeloma (NDTEMM) [routes not stated]. The patient, who had NDTEMM with cytogenetic abnormality, had received induction therapy with bortezomib, thalidomide and dexamethasone (VTD regimen) [initial dosages not stated]. Eventually, the patient started receiving maintenance therapy with bortezomib 1.3 mg/m2 from January 2011 and then dexamethasone 20mg, every 2 weeks for up to 2 years. However, the patient developed severe toxicity in the form of massive DVT, which was considered to be related to bortezomib and dexamethasone [time to reaction onset not stated]. Thereafter, the patient’s therapy with bortezomib and dexamethasone was discontinued [outcome not stated]. Author comment: "We retrospectively analyzed 34 NDTEMM [patients] who received maintenance therapy . . . with [bortezomib] . . . and dexamethasone". "At the time of analysis, . . . 13 had premature withdrawal due to either disease progression (12 [patients], 39%) or (1 patient) severe toxicity (massive DVT)." Mancuso K, et al. Maintenance therapy with bortezomib/dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients carrying high risk features. Haematologica 104 (Suppl. 2): 50 abstr. C089, Oct 2019. Available from: URL: http://www.haematologica.org/content/104/s2/1.full.pdf+html [abstract] 803433891 Italy

0114-9954/19/1779-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved

Reactions 16 Nov 2019 No. 1779